MX352778B - Pharmaceutical composition with a selective enzyme phosphodiesterase inhibitor in an oral gel form. - Google Patents

Pharmaceutical composition with a selective enzyme phosphodiesterase inhibitor in an oral gel form.

Info

Publication number
MX352778B
MX352778B MX2015007502A MX2015007502A MX352778B MX 352778 B MX352778 B MX 352778B MX 2015007502 A MX2015007502 A MX 2015007502A MX 2015007502 A MX2015007502 A MX 2015007502A MX 352778 B MX352778 B MX 352778B
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
phosphodiesterase inhibitor
selective enzyme
gel form
enzyme phosphodiesterase
Prior art date
Application number
MX2015007502A
Other languages
Spanish (es)
Inventor
Ángel García Pérez Miguel
Marcelín Jiménez Gabriel
Albina Vázquez Flores Concepción
Citlali P Angeles Moreno Alionka
Caro Rodríguez Octavio
David Ávila Cedillo Ricardo
Original Assignee
Miguel Angel Garcia Perez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miguel Angel Garcia Perez filed Critical Miguel Angel Garcia Perez
Priority to MX2015007502A priority Critical patent/MX352778B/en
Publication of MX352778B publication Critical patent/MX352778B/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention refers to a novel pharmaceutical composition of modified release for being orally administered in a liquid and/or semisolid form, which contains a therapeutically effective amount of at least a selective enzyme phosphodiesterase inhibitor agent or the pharmaceutically acceptable salts thereof, combined with one or more solvents and/or co-solvents and/or one or more pharmaceutically acceptable salts thereof. The novel composition of the present invention may achieve maximum plasmatic concentrations for a longer period of time, i.e., the release and absorption of sildenafil by the administration of the novel composition is performed in a sustained manner with a gradual absorption.
MX2015007502A 2013-01-31 2013-01-31 Pharmaceutical composition with a selective enzyme phosphodiesterase inhibitor in an oral gel form. MX352778B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2015007502A MX352778B (en) 2013-01-31 2013-01-31 Pharmaceutical composition with a selective enzyme phosphodiesterase inhibitor in an oral gel form.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2015007502A MX352778B (en) 2013-01-31 2013-01-31 Pharmaceutical composition with a selective enzyme phosphodiesterase inhibitor in an oral gel form.

Publications (1)

Publication Number Publication Date
MX352778B true MX352778B (en) 2017-09-27

Family

ID=62778581

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015007502A MX352778B (en) 2013-01-31 2013-01-31 Pharmaceutical composition with a selective enzyme phosphodiesterase inhibitor in an oral gel form.

Country Status (1)

Country Link
MX (1) MX352778B (en)

Similar Documents

Publication Publication Date Title
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
EA201690223A1 (en) FACTOR INHIBITORS IN THE COMPLEMENT BASED ON PIPERIDININILINDOL DERIVATIVES AND THEIR APPLICATION
EA201592256A1 (en) DERIVATIVES OF IMIDAZOPIRROLIDINONE AND THEIR APPLICATION IN THE TREATMENT OF DISEASES
BR112017007662A8 (en) Compound, pharmaceutical composition and use of a compound
EA201690287A1 (en) 1,4-DESIGNED ANALOGUES OF PYRIDAZIN QUINOLINE AND METHODS OF TREATING CONDITIONS ASSOCIATED WITH SMN-DEFICIENCY
PH12016500024A1 (en) Bromodomain inhibitor
EA201591751A1 (en) TRIPEPTIDE EPOKEKETONE PROTEASE INHIBITORS
AR091876A1 (en) PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
TR201904455T4 (en) 1,2,4-triazoles and their uses as nuclear transport modulators.
UA114906C2 (en) Heterocyclyl compounds
EA201591363A1 (en) TIADIAZOLE ANALOGUES AND METHODS OF TREATMENT OF STATES ASSOCIATED WITH SMN DEFICIENCY
MX2015016421A (en) Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease.
BR112018015718A2 (en) use of sgc stimulators for the treatment of nonalcoholic steatohepatitis (nash)
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
MX2016002580A (en) Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases.
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
EA201692481A1 (en) COMBINATION CONTAINING GLUCOCORTICOID AND EDO-S101
EA201692276A1 (en) COMBINATION OF TIOTROPY OF BROMIDE, FORMOTEROL AND BUDESONIDE FOR THE TREATMENT OF COPD
AR086800A1 (en) TOPICA OPHTHALMOLOGICAL PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB
MX2013001279A (en) Pharmaceutical composition with a selective enzyme phosphodiesterase inhibitor in an oral gel form.
MX2015012153A (en) Pyrrolopyrimindine cdk9 kinase inhibitors.
CY1122598T1 (en) OPHTHALMIC PHARMACEUTICAL COMPOSITION CONTAINING CARBONATION INHIBITOR AND METHOD FOR PREPARATION THEREOF
TR201310724A2 (en) Pharmaceutical formulati̇ons of linagliptin
CL2016002655A1 (en) Pharmaceutical composition for the treatment of pain-related allopathies, using as active agent ketorolac tromethamine and tramadol hydrochloride
MX352778B (en) Pharmaceutical composition with a selective enzyme phosphodiesterase inhibitor in an oral gel form.